These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9129655)

  • 1. The non-immunosuppressive cyclosporin A analogue SDZ NIM 811 inhibits cyclophilin A incorporation into virions and virus replication in human immunodeficiency virus type 1-infected primary and growth-arrested T cells.
    Mlynar E; Bevec D; Billich A; Rosenwirth B; Steinkasserer A
    J Gen Virol; 1997 Apr; 78 ( Pt 4)():825-35. PubMed ID: 9129655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: interference with HIV protein-cyclophilin A interactions.
    Billich A; Hammerschmid F; Peichl P; Wenger R; Zenke G; Quesniaux V; Rosenwirth B
    J Virol; 1995 Apr; 69(4):2451-61. PubMed ID: 7884893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus type 1 (HIV-1): interference with early and late events in HIV-1 replication.
    Steinkasserer A; Harrison R; Billich A; Hammerschmid F; Werner G; Wolff B; Peichl P; Palfi G; Schnitzel W; Mlynar E
    J Virol; 1995 Feb; 69(2):814-24. PubMed ID: 7815548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The human immunodeficiency virus type 1 capsid p2 domain confers sensitivity to the cyclophilin-binding drug SDZ NIM 811.
    Dorfman T; Göttlinger HG
    J Virol; 1996 Sep; 70(9):5751-7. PubMed ID: 8709190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog.
    Rosenwirth B; Billich A; Datema R; Donatsch P; Hammerschmid F; Harrison R; Hiestand P; Jaksche H; Mayer P; Peichl P
    Antimicrob Agents Chemother; 1994 Aug; 38(8):1763-72. PubMed ID: 7527198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional association of cyclophilin A with HIV-1 virions.
    Thali M; Bukovsky A; Kondo E; Rosenwirth B; Walsh CT; Sodroski J; Göttlinger HG
    Nature; 1994 Nov; 372(6504):363-5. PubMed ID: 7969495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel activities of cyclophilin A and cyclosporin A during HIV-1 infection of primary lymphocytes and macrophages.
    Saini M; Potash MJ
    J Immunol; 2006 Jul; 177(1):443-9. PubMed ID: 16785541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclophilin a modulates processing of human immunodeficiency virus type 1 p55Gag: mechanism for antiviral effects of cyclosporin A.
    Streblow DN; Kitabwalla M; Malkovsky M; Pauza CD
    Virology; 1998 Jun; 245(2):197-202. PubMed ID: 9636359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic independence of Nef and cyclophilin A enhancement of human immunodeficiency virus type 1 infectivity.
    Aiken C
    Virology; 1998 Aug; 248(1):139-47. PubMed ID: 9705263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of cyclosporin A on the replication cycle of human immunodeficiency virus type 1 derived from H9 and Molt-4 producer cells.
    Briggs CJ; Tözsér J; Oroszlan S
    J Gen Virol; 1996 Dec; 77 ( Pt 12)():2963-7. PubMed ID: 9000086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Debio-025 inhibits HIV-1 by interfering with an early event in the replication cycle.
    Daelemans D; Dumont JM; Rosenwirth B; De Clercq E; Pannecouque C
    Antiviral Res; 2010 Feb; 85(2):418-21. PubMed ID: 19857522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of HIV-1 replication and infectivity by expression of a fusion protein, VPR-anti-integrase single-chain variable fragment (SFv): intravirion molecular therapies.
    BouHamdan M; Kulkosky J; Duan LX; Pomerantz RJ
    J Hum Virol; 2000; 3(1):6-15. PubMed ID: 10774802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclosporine blocks incorporation of HIV-1 envelope glycoprotein into virions.
    Sokolskaja E; Olivari S; Zufferey M; Strambio-De-Castillia C; Pizzato M; Luban J
    J Virol; 2010 May; 84(9):4851-5. PubMed ID: 20181694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based identification of small molecule compounds targeting cell cyclophilin A with anti-HIV-1 activity.
    Chen S; Zhao X; Tan J; Lu H; Qi Z; Huang Q; Zeng X; Zhang M; Jiang S; Jiang H; Yu L
    Eur J Pharmacol; 2007 Jun; 565(1-3):54-9. PubMed ID: 17449029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIV(CPZ)GAB but not group O HIV-1 or other primate immunodeficiency viruses.
    Braaten D; Franke EK; Luban J
    J Virol; 1996 Jul; 70(7):4220-7. PubMed ID: 8676442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific incorporation of cyclophilin A into HIV-1 virions.
    Franke EK; Yuan HE; Luban J
    Nature; 1994 Nov; 372(6504):359-62. PubMed ID: 7969494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells.
    Braaten D; Luban J
    EMBO J; 2001 Mar; 20(6):1300-9. PubMed ID: 11250896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A mutation in alpha helix 3 of CA renders human immunodeficiency virus type 1 cyclosporin A resistant and dependent: rescue by a second-site substitution in a distal region of CA.
    Yang R; Aiken C
    J Virol; 2007 Apr; 81(8):3749-56. PubMed ID: 17267487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity.
    Sokolskaja E; Sayah DM; Luban J
    J Virol; 2004 Dec; 78(23):12800-8. PubMed ID: 15542632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction.
    Franke EK; Luban J
    Virology; 1996 Aug; 222(1):279-82. PubMed ID: 8806510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.